Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A

Seeking AlphaJul 13 14:03 ET

UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $43

UBS analyst Trung Huynh maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and adjusts the target price from $52 to $43.According to TipRanks data, the analyst has a success rate of 75.5%

Moomoo NewsJul 12 11:31 ET · Ratings

Express News | Bristol-Myers Squibb Co : UBS Cuts Target Price to $43 From $47

ReutersJul 12 08:42 ET

Barclays Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $41

Barclays analyst Carter Gould maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate of 57.7%

Moomoo NewsJul 12 04:31 ET · Ratings

Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Cuts Target Price to $37

Morgan Stanley analyst Terence Flynn maintains $Bristol-Myers Squibb(BMY.US)$ with a sell rating, and adjusts the target price from $40 to $37.According to TipRanks data, the analyst has a success

Moomoo NewsJul 11 09:34 ET · Ratings

Morgan Stanley Sticks to Its Sell Rating for Bristol-Myers Squibb (BMY)

TipRanksJul 11 08:46 ET